Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06763172 · ClinicalTrials.gov registry record · Phase 4
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
A Phase 4 study of Healthy and Caffeine, sponsored by Hsiao-Ying Wey.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06763172 is a Phase 4 study of Healthy and Caffeine that is actively recruiting participants, run by Hsiao-Ying Wey. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06763172, a Phase 4 study of Healthy and Caffeine, is actively recruiting participants, sponsored by Hsiao-Ying Wey.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired from this study would improve our understanding on the consequence and mechanism of caffeine intake in the aspect of learning process. Participants will perform a reinforcement learning task (i.e. Probabilistic Selection Task) and a motor inhibition task (i.e. Go/NoGo task) in a brain scan. The scan will be done with the Siemens Biograph mMR positron emission tomography (PET)/ magnetic resonance imaging (MRI) 3 Tesla scanner. The PET allows us to see the changes in the "reward signals" - dopamine - in the brain using a radioactive dye called \[11C\]Raclopride. The MRI, on the other hand, enables us to take detailed pictures of the brain activities during cognitive tasks using a high-powered magnet. Reviewing these pictures will help us understand the influence of caffeine on reward signals and brain activities during the learning process.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Caffeine (200 mg)
Study Locations (1)
Massachusetts
- Athinoula A. Martinos Center for Biomedical Imaging - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-05-17 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06763172
The ClinicalTrials.gov registry entry for NCT06763172 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Hsiao-Ying Wey, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06763172 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06763172 about?
NCT06763172 is a clinical study titled "Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI". This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired from this study would improve our understanding on the consequence and mechanism of caffeine intake in the aspect of learning process. Partic...
What is the current status of trial NCT06763172?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2023-05-17. Estimated completion is 2026-12-31.
What conditions does trial NCT06763172 study?
This clinical trial studies the following conditions: Healthy, Caffeine, Adenosine, Dopamine D2/3 Receptor Availability.
What interventions are being tested in trial NCT06763172?
The interventions under investigation include: Placebo (DRUG), Caffeine (200 mg) (DRUG).
Who is sponsoring clinical trial NCT06763172?
This trial is sponsored by Hsiao-Ying Wey, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06763172 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
-
VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.